Karyopharm Therapeutics Ownership
| KPTI Stock | USD 4.02 0.17 4.42% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 4.1 M | Current Value 4.1 M | Avarage Shares Outstanding 9.4 M | Quarterly Volatility 21.1 M |
Karyopharm | Build AI portfolio with Karyopharm Stock |
Karyopharm Stock Ownership Analysis
About 43.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 11.87. Karyopharm Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 26th of February 2025. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people. To find out more about Karyopharm Therapeutics contact Richard MBA at 617 658 0600 or learn more at https://www.karyopharm.com.Karyopharm Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Karyopharm Therapeutics' institutional investor refers to the entity that pools money to purchase Karyopharm Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2025-03-31 | 132.9 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 128.5 K | Cam Group Holding A/s | 2025-03-31 | 100 K | Geode Capital Management, Llc | 2025-03-31 | 99.6 K | Ubs Group Ag | 2025-03-31 | 93.6 K | Goldman Sachs Group Inc | 2025-03-31 | 85.4 K | Renaissance Technologies Corp | 2025-03-31 | 61.2 K | Millennium Management Llc | 2025-03-31 | 55.4 K | Silverback Aset Management Llc | 2025-03-31 | 50 K | Palo Alto Investors, Llc | 2024-12-31 | 4.9 M | Vanguard Group Inc | 2025-03-31 | 510.3 K |
Karyopharm Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Karyopharm Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Karyopharm Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Karyopharm Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karyopharm Therapeutics Outstanding Bonds
Karyopharm Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Karyopharm Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Karyopharm bonds can be classified according to their maturity, which is the date when Karyopharm Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.87) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.